TCTR20240605002尚未招募2 期
Phase 2, randomized, double-blind, two-way crossover, placebo-controlled clinical trial of the efficacy and safety of Mucuna pruriens seed extract in men with mild and mild to moderate erectile dysfunction
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20 Years 至 60 Years（—）
- 性别
- Male
入选标准
- •1. Male participants aged 20-60 years, who can read and write Thai, 2. Have had erectile dysfunction problems for at least 3 months, 3. Have mild and mild to moderate erectile dysfunction (a score of 12 - 21 on the International Index of Erectile Function (IIEF-5) questionnaire), 4. Willing to have sex at least 1 time in 2 weeks throughout the study, 5. Agree not to use other methods of treating erectile dysfunction including other herbs throughout the study period, 6. Research participants must be informed of the details of the clinical study, including risks and side effects that may occur during the study period, both verbally and in writing. They must sign the consent form to participate in the research voluntarily.
排除标准
- •1. Currently using phosphodiesterase-5 inhibitors or have stopped using them for less than 1 week, 2. Erectile dysfunction caused by nerve injury due to spinal cord injuries or surgery on the colon, rectum, prostate, bladder, etc., 3. A history of being allergic to M. pruriens., 4. Smoke more than 20 cigarettes per day, 5. Have heart disease, 6. Have kidney disease, 7. Have uncontrolled hypertension, 8. Patients with uncontrolled diabetes, 9. Have uncontrolled hypercholesterolemia, 10. Have ever had surgery or radiation on the pelvic region or other conditions that may affect the effectiveness of M. pruriens seed extract, 11. Have cancer, 12. Have clinically significant abnormalities in the results of routine laboratory tests.
研究者
相似试验
进行中（未招募）
不适用
Clinical Trial, Phase II, randomized, double-blind, placebo-controlled, 1-way over with 2 treatment periods of 40 weeks duration.Applicants: Research Group CTS546. IBIMA. Regional University Hospital. Málaga.Subjects: Patients above 55 years with depressive disorders.EUCTR2013-004276-35-ESHospital Regional Universitario. IBIMA
进行中（未招募）
1 期
A Phase II, double-blind, randomized, cross-over, international,multicentre study to evaluate the analgesic efficacy of 3 weeks oraladministration of AZD4282 300 mg b.i.d. compared with placebo inposttraumatic neuralgiaDiagnostic of Post Traumatic NeuralgiaEUCTR2004-004907-39-DKAstraZeneca AB60
进行中（未招募）
1 期
A Phase II, double-blind, randomized, cross-over, international,multicentre study to evaluate the analgesic efficacy of 3 weeks oraladministration of AZD4282 300 mg b.i.d. compared with placebo inpostherpetic neuralgiaDiagnosis of postherpetic neuralgiaEUCTR2004-004908-21-DKAstraZeneca AB60
招募中
2 期
Phase II, randomized, double-blind, crossover, placebo-controlled clinical trial to evaluate the efficacy and safety of Esketamine as an adjunct to standard care in patients with Obsessive-Compulsive Disorder- OCDobsessive-compulsive disorderRBR-6kmdtgbHospital Universitário Professor Edgard Santos
进行中（未招募）
不适用
A study to compare the efficacy and safety of different dosings of olodaterol administered with the Respimat® Inhaler in patients with moderate to severe asthmaModerate to severe persistent asthmaMedDRA version: 13.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2008-006625-14-DEBoehringer Ingelheim Pharma GmbH & Co. KG180